Intel surges more than 8% after chipmaker’s profits top expectations
GSK plc (LSE/NYSE:GSK) announced Wednesday that its next-generation low carbon version of the Ventolin (salbutamol) metered dose inhaler (MDI) achieved positive results in pivotal phase III clinical trials. According to a press release statement, data from the clinical program confirmed the therapeutic equivalence and comparable safety profile of the new inhaler, which uses the low carbon propellant HFA-152a, compared to the current version using HFA-134a.
The company stated that approximately 300 million salbutamol MDIs are sold globally each year. GSK’s salbutamol MDI currently accounts for about 45% of the company’s total global carbon footprint, based on its 2024 annual report.
The new version of the inhaler, if approved, is expected to reduce greenhouse gas emissions by 92% per inhaler, based on life cycle assessment data cited in the filing. GSK plans to proceed with regulatory submissions and anticipates a product launch beginning in 2026.
Kaivan Khavandi, GSK’s global head of respiratory, immunology and inflammation R&D, said in the statement, “Healthy air is essential for healthy lungs, and our next-generation salbutamol has the potential to reduce greenhouse gas emissions by 92% per inhaler.”
The company noted that while alternative inhaler technologies such as dry powder and soft mist inhalers exist, many patients with asthma and chronic obstructive pulmonary disease (COPD) prefer the metered dose inhaler format.
The information in this article is based on a press release statement included in a regulatory filing with the U.S. Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.